M&A Deals: Monthly Monitor November

2 December 2015
mergers-acquisitions-big

November – The year 2015 is set to go down as the biggest ever in terms of acquisitions deals as pharma giant Pfizer (NYSE: PFE) and Botox-maker Allergan (NYSE: AGN) set out to create the largest drug company in the world.  Valued at $160 billion, the deal comes close on the heels of Pfizer’s $17 billion acquisition of Hospira and a failed attempt to grab UK drug major AstraZeneca (LSE: AZN).

The total deal vale for the year so far has touched $3.29 trillion, ahead of the $3.27 trillion recorded for the full-year 2014, according to data from Mergermarket. Given the pace of M&A activity it may not be wrong to estimate the year is likely to surpass the record deal value of $3.67 trillion witnessed in the year 2007.

Overall, a series of other big ticket deals in the pharma/biotech sector has marked the year as the strongest period of mergers and acquisition activity.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical